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ABSTRACT 
In this work we propose the Nuclear Quadrupole Resonance (NQR) technique as an 
analytical method suitable for polymorphism detection in active parts (or active principles) 
of pharmaceuticals with high pharmacological risk. Samples of powder carbamazepine 
(5H-dibenz(b,f)-azepine-5-carboxamide) are studied. In its anhydrous state, this compound 
presents at least three different polymorphic forms: form III, the commercial one, form II, 
and form I. Of these, only form III possesses desirable therapeutic effects. By using the 
NQR technique, it was possible to characterize two of the three polymorphic phases (I and 
III) for anhydrous carbamazepine in few minutes at room temperature, detecting the 
characteristic frequencies of  14N nuclei (I=1) present in their chemical composition and in 
the frequency range 2.820—3.935 MHz. For form II, characteristic lines were not detected 
within this range of frequencies. The lines detected for form III are centered at the 
frequencies ν1III=3.876 MHz, ν2III=3.829 MHz, and ν3III=2.909 MHz; and for form I 
centered at ν1I=3.876 MHz, ν2I=3.840 MHz, ν3I=2.911 MHz, and ν4I=2.830 MHz. 
Keywords: Carbamazepine, NQR , Polymorphism, Solid State Characterization. 
 
 
 
 
I. INTRODUCTION 
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In the last decades, it has been proved that once a compound with pharmacological 
applications is developed, the characterization of its solid state is one of the most important 
stages for the development of the pharmaceuticals. An appropriate characterization is 
needed since solid pharmacological forms can be presented as different polymorphs, 
solvates or amorphous forms, which generally have different bioavailabilities and clinical 
use 1.  
Polymorphism is the crystallization of the same compound in more than one distinct 
crystal architecture and is associated with different crystal packing arrangements. This 
phenomenon is very common in pharmacological drugs, as it is the case of carbamazepine 
(5H-dibenz(b,f)-azepine-5-carboxamide). This drug whose chemical formula is C15H12N2O  
has been in routine use in the treatment of epilepsy and trigeminal neuralgia for over 30 
years. Three different polymorphic forms have been confirmed for the anhydrous 
carbamazepine 2: form III, the commercial one, form I, and form II (nomenclature as Krahn 
and Mielck 3 and Behme and Brooke 4); nevertheless, certain analytical results suggest the 
existence of additional forms and the formation of mixed crystals. 
In spite of possessing the same active part (molecule), polymorphs have different 
chemical and physical properties; they have different melting points, different chemical 
reactivity, different dissolution rates, and different bioavailability (polymorph III of 
carbamazepine is the only one that has desirable therapeutic effects). Polymorphs can be 
interconverted by phase transformations or by a solvent-mediated process. Phase 
transformations can also be induced by heat or mechanical stress 2. 
It is important to highlight that the Food and Drug Administration requires analytical 
procedures for the detection of polymorphic, hydrated, or amorphous forms in the drug 
substances, and that in certain cases the polymorphs of an active part pass the conventional 
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pharmacological tests, since these analyze the compound mainly in solutions. For this 
reason, it is essential to have other techniques implemented to study these phenomena. 
Since the sixties, it is well known that the Nuclear Quadrupole Resonance (NQR) 5, 6 
technique is useful for studying basic aspects of crystalline phase transitions that involve 
different polymorphs. This technique together with the NMR (Nuclear Magnetic 
Resonance) has proved to be very sensitive for the microscopic study of diverse dynamic 
and structural properties of the atoms that constitute the solids. In particular, the sensitivity 
of the NQR frequency in the face of structural changes in the crystal converts this into a 
very appropriate spectroscopic technique for the detection of these structural changes in 
organic compounds, as well as for the comparative study of the molecular dynamics 
corresponding to different polymorphic forms, polymorphic phases transitions, etc. (see 
Refs. 5--10 and references therein). Therefore, the NQR technique is a valid alternative to 
compare active parts, avoiding the need of using bioavailabilities studies in vivo. 
With regard to X-Ray powder diffraction and calorimetry techniques, the NQR 
implementation is technologically simpler and cheaper. In relation to the first one, it is not 
necessary to irradiate the sample (and eventually the environment) with ionizing radiations, 
but short and innocuous long wavelength radio frequencies (rf) pulses. As regards the 
second one, the analysis is performed at room temperature and in few seconds, without the 
necessity of high temperatures that in many cases lead to the decomposition of the 
compound. Another important aspect to be pointed out is that samples do not require 
previous preparation and can be used again. On the other hand, the analysis can be carried 
out directly in the pure drug as in the medication and it can be quantitative, regarding the 
total of the active part contained in the pharmaceutical formulation. The time required for 
the analysis can be reduced to a few seconds, and in some favorable cases, to even shorter 
periods. Since the action on the sample is innocuous, it is feasible to develop devices to 
control the final product directly in the production line. The analytic equipment can be 
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implemented daily and controlled by means of a PC, so that highly qualified staff is not 
needed for its operation. 
The aim of this work is to characterize the different polymorphic states of anhydrous 
carbamazepine (forms I, II and III) by the 14N (I=1) NQR, through the evaluation of the 
characteristic NQR frequencies at room temperature. 
 
II. EXPERIMENTAL 
 
The experiments were carried out using 14N nuclei in a powder sample of carbamazepine, 
at room temperature, and the SpinLock QR20 broad band (0.4–20MHz) NQR spectrometer 
(see www.spinlock.com.ar for technical details). The signals were processed with an had 
hoc software provided by the SPINLOCK Software Department. 
   
A. MATERIALS 
 
Carbamazepine samples in their polymorphic phases I, II, and III (nomenclature as Refs. 
3 and 4) were provided by the Pharmaceutical Laboratory QUÍMICA LUAR S.R.L. 
(Córdoba-Argentina). At first sight, these polymorphs in their pure state look like a white 
thick powder for polymorphs I and III, and a white fine powder for polymorph II. 
Carbamazepine form III was analyzed by X-Ray Powder Diffraction and Fourier 
Transform Infrared Spectroscopy techniques according to USP XXIV in the National 
Organism CEPROCOR (Córdoba-Argentina). The analysis determined that the sample 
corresponds to carbamazepine polymorph III (monoclinic structure 11) without the presence 
of other polymorphs. Technical characteristics of carbamazepine can be found in Refs. 2—
4, 11—15. 
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B. SAMPLES PREPARATION 
 
The samples were vacuum-packed in glass vessels of 113 cm3. Two of them were filled 
with 50g carbamazepine polymorph I and III, respectively; while the other was filled with 
43g of the form II. According to the literature 13, polymorph I (trigonal form) was obtained 
by heating form III in an oven at 140ºC for 9 h; polymorph II was obtained from freshly 
prepared carbamazepine dihydrate by dehydrating at 20ºC in a vacuum desiccator over 
P2O5 Ref. 3; and form III was obtained by cooling boiled acetone solution of commercial 
carbamazepine 13.  
 
C. EXPERIMENTAL TECHNIQUE 
To find the NQR characteristic frequencies of 14N * nuclei in polymorphs I, II, and III, a 
sweeping-frequency was made by 5kHz-steps over the 2.820--3.935 MHz range and 
retuning the probe each 40kHz. For spectral line detection, CPMG rf pulses sequence16 was 
used, which consists of an initial 90º|x pulse, followed by a train of 180º|y pulses, i.e., 90º 
phase shift. The length for 90º and 180º rf pulses was about 35 and 50µs respectively. The 
interval between the 90º|x and 180º|y pulses was 800µs, and the interval between 180º|y 
pulses was 1600 µs. The length of the pulse train was 30ms. By this sequence, the echo 
signals, formed between the 180º|y pulses of the train, were acquired and added. In order to 
improve signal-to-noise ratio (S/N), the NQR echo signal is take as an average value of 
about 50 pulse train measurements. The spectra were obtained by Fast Fourier Transform 
(FFT) of the signals. It is important to wait for some time after each pulse train so that the 
14N spin system relaxes and reaches thermal equilibrium with surroundings (lattice). 
                                                 
* Generally, the NQR characteristic frequencies of 14N nuclei are in the frequency band 2—5 MHz. 
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Generally, a 5T1-order delay is chosen where T1 is the spin-lattice relaxation time 16, 17. In 
order to minimize the measurement time, a 5s-delay was chosen.†  
 
III. RESULTS AND ANALYSIS  
 
For polymorph III, three NQR characteristic narrow lines were detected, each belonging 
to the 5kHz order, likely to be compound and centered at the characteristic frequencies: 
ν1III=3.876 MHz, ν2III=3.829 MHz and ν3III=2.909 MHz, respectively. The experimental 
spectrum for polymorph III is shown in Fig. 1. 
The most intense line corresponds to frequency ν1III and the less intense one is centered at 
ν3III (see Fig. 1).  
A more detailed analysis of spectral lines shows, in fact, that these are multiple 
Gaussians-like lines. The number of these composing lines, their intensities and their 
widths were determined by an appropriate software. For this analysis, the irrelevant points 
of lines were eliminated, taking into account only those whose intensities were greater than 
the average intensity of thermal-noise signal. The adopted criteria for composing lines 
number determination was the following: in the first place, the line was fit with a Gaussian 
curve of the form ( ) ( ) ( )  −−= 222120 22 aaxaaxy exp)( π and then we continue adding 
other Gaussian curves, keeping a0, a1 and a2 parameters free, until being able to reproduce 
the measured line by using the smallest number of such curves. Once the confidence 
parameters provided by the software were the optimum ones (correlation parameter r2~1 
and merit factor F >>1) lines (or curves) were no longer added. On the other hand, we used 
                                                 
† With the rf pulse sequence 90º|y—t1--90º|y--τ--90º|x--2τ--90º|x…, it was possible to measure the spin-lattice 
relaxation time T1; and for the polymorph III at characteristic frequency ν2III=3.829 MHz it was 
T1=(3697±123)ms. 
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other kinds of curves, namely Lorentzian-like and combinations of Lorentzians and 
Gaussians, and the best adjustments were obtained by Gaussian curves. The lines 
determined in this way are listed in Tables I(a)--I(c) (see Figs. 2(a)--2(c)). 
In polymorph I, four NQR characteristic lines were detected, each belonging to the 
10kHz order and also likely to be compound. These lines are centered at: ν1I=3.876 MHz, 
ν2I=3.840 MHz, ν3I=2.911 MHz and ν4I=2.830 MHz, respectively, and they are shown in 
Fig. 3. 
The most intense line corresponds to the frequency ν1I, ν2I follows in intensity, and the 
less intense one is centered at ν3I (see Fig. 3).  
For the determination of composing lines, we followed the same procedure as for 
polymorph III, obtaining the results shown in Tables II(a)—II(d) (see Figs. 4(a)—4(d)). 
 
IV. CONCLUSIONS 
 
A complete evaluation of possible variations in crystallography of compounds of 
pharmacological interest is now essential for the development of new and more effective 
medicines. The sensitivity of NQR frequency in the face of structural changes in the crystal 
turns this into a very appropriate technique for polymorphisms characterization in active 
parts, avoiding the need of carrying out bioequivalence studies in vivo, which come to be 
extremely risky for individuals. It is quite feasible to develop devices to be used in the 
pharmaceutical and chemical industry since they are relatively economical and easy to be 
implemented. 
The literature shows that the structure of polymorph I is more complex than that of 
polymorph III because the form I presents a greater disorder in its crystal structure. 
Polymorph I (trigonal structure) has a higher number of molecules per unit cell (eighteen), 
while polymorph III (monoclinic structure) has four molecules per unit cell15. These 
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characteristics are proved by observing the corresponding spectra, which are 
experimentally measured and shown in Sec. III. For polymorph III, three NQR 
characteristic lines of 14N (I=1) nuclei were detected, each belonging to the 5kHz order, 
likely to be compound and centered at the following frequencies: ν1III=3.876 MHz, 
ν2III=3.829 MHz, and ν3III=2.909 MHz respectively. For polymorph I, on the other hand, 
four wider NQR lines were observed, each belonging to the 10kHz order and being likely 
to be compound, too. These lines are centered at the characteristic frequencies: ν1I=3.876 
MHz, ν2I=3.840 MHz, ν3I=2.911 MHz, and ν4I=2.830 MHz respectively. A greater number 
of spectral lines in polymorph I would be consistent with the presence of a higher number 
of non-equivalent 14N nuclei in unit cell. As regards polymorph II, it was not possible to 
detect its characteristic frequencies within the frequencies range 2.820--3.935MHz. This 
might be due to the fact that this polymorph presents a disorder degree in its crystal 
structure that is even higher than those of polymorphs I and III. 
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Figure legends 
 
 
Figure 1: NQR spectrum of carbamazepine polymorph III, measured at room temperature 
       in frequency range 2.820—3.935 MHz. 
 
Figure 2(a): Components of polymorph III line at ν1III=3.876 MHz. 
           2(b): Components of polymorph III line at ν2III=3.829 MHz. 
           2(c): Components of polymorph III line at ν3III=2.909 MHz. 
 
Figure 3: NQR spectrum of carbamazepine polymorph I, measured at room temperature               
        in frequency range 2.820—3.935 MHz. 
 
Figure 4(a): Components of polymorph I line at ν1I=3.876 MHz. 
           4(b): Components of polymorph I line at ν2I=3.840 MHz. 
           4(c): Components of polymorph I line at ν3I=2.911 MHz. 
           4(d): Components of polymorph I line at ν4I=2.830 MHz. 
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Table I(a): Amplitudes and widths of the composing lines of the line centered at           
        ν1III=3.876. 
Frequency 
(MHz) 
Component 
frequencies (MHz) 
Amplitudes 
(arbitrary units) 
Composing  line 
widths  (KHz) 
3.873 242 1.5 
3.874 138 1 
3.875 899 2 
3.877 1368 2 
3.878 262 1.5 
 
 
ν1III=3.876 
3.880 185 1.5 
 
 
Table I(b): Amplitudes and widths of the composing lines of the line centered at      
         ν2III=3.829. 
Frequency 
(MHz) 
Component 
frequencies (MHz) 
Amplitudes 
(arbitrary units) 
Composing  line 
widths (KHz) 
3.824 168 2 
3.826 60 1 
3.829 1141 3.5 
3.831 223 2.5 
3.834 102 1 
 
 
ν2III=3.829 
3.835 192 1.5 
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Table I(c): Amplitudes and widths of the composing lines of the line centered at  
          ν3III=2.909. 
Frequency 
(MHz) 
Component 
frequencies (MHz) 
Amplitudes 
(arbitrary units.) 
Composing  line 
widths (KHz) 
2.903 25 3.5 
2.907 17 2 
2.908 61 3 
2.910 298 4.5 
2.914 25 4 
 
 
ν3III=2.909 
2.919 14 4 
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Table II(a): Amplitudes and widths of the composing lines of the line centered at    
         ν1I=3.876. This line is composed by five Gaussian lines mounted on a            
          base-line. 
Frequency 
(MHz) 
Component 
frequencies (MHz) 
Amplitudes 
(arbitrary units) 
Composing  line 
widths (KHz) 
3.868 120 3.5 
3.869 80 4.5 
3.875 277 4 
3.880 17 2.5 
 
 
ν1I=3.876 
3.883 20 4 
 
 
 
Table II(b): Amplitudes and widths of the composing lines of the line centered at     
          ν2I=3.840. 
Frequency 
(MHz) 
Component 
frequencies (MHz) 
Amplitudes 
(arbitrary units) 
Composing  line 
widths (KHz) 
3.830 11 2 
3.833 26 3.5 
3.836 19 2 
3.840 207 4.5 
3.843 13 2 
 
 
ν2I=3.840 
3.847 18 7 
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Table II(c): Amplitudes and widths of the composing lines of the line centered at  
          ν3I=2.911. 
Frequency 
(MHz) 
Component 
frequencies (MHz) 
Amplitudes 
(arbitrary units) 
Composing  line 
widths (KHz) 
2.897 2 4 
2.901 4 3 
2.907 18 5 
2.912 39 8.5 
2.920 5 2.5 
 
 
ν3I=2.911 
2.921 2 1.5 
 
 
Table II(d): Amplitudes and widths of the composing lines of the line centered at  
          ν4I=2.830. 
Frequency 
(MHz) 
Component 
frequencies (MHz) 
Amplitudes 
(arbitrary units) 
Composing  line 
widths (KHz) 
2.819 7 5 
2.822 10 3 
2.826 16 4.5 
2.830 6 3 
2.831 39 6.5 
2.837 5 3 
 
 
ν4I=2.830 
2.840 3 3.5 
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Figure 1 
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Figure 2(a) 
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Figure 2(b) 
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Figure 2(c) 
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Figure 3 
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Figure 4(a) 
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Figure 4(b) 
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Figure 4(c) 
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Figure 4(d) 
 
